Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
Status:
Terminated
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for
28 days in patients with Huntington's Disease (HD).